Praxis Precision Medicines (PRAX) said Monday the US Food and Drug Administration accepted its priority review new drug application for relutrigine to treat developmental and epileptic encephalopathies.
The regulatory agency established a decision deadline of Sept. 27 for the medication, which is backed by favorable data from the EMBOLD trial that concluded prematurely due to demonstrated efficacy, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.